With a goal of expanding manufacturing capabilities to meet the growing demands of cell and gene therapy production, The Center for Breakthrough Medicines (CBM) promoted Chief Operating Officer Joerg Ahlgrimm to the role of Chief Executive Officer. Ahlgrimm joined CBM last year after serving as Head of Global Operations Pharma Biotech and Nutrition at Lonza. CBM, located within the Discovery Labs campus in suburban Philadelphia, is a quickly growing contract development and manufacturing organization that aims to provide pre-clinical through commercial manufacturing capabilities for client companies. CBM’s offerings include process development, plasmid DNA, viral vectors, cell banking, cell processing, and supporting testing capabilities.
Altasciences today announced the continued expansion of their formulation, manufacturing, and analytical services facilities in Philadelphia, PA. Altasciences, an integrated drug development solution company offering pharmaceutical and biotechnology companies worldwide a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services, launched a second building project to increase its capacity and meet the ever-growing needs of its clients.
Cell therapies have grown to become a prevailing field dominating new medical breakthroughs with the promise of treatments and cures for multiple diseases. The biopharma hubs of Philadelphia and Maryland have emerged as important drivers of this new wave of medicine, build on the foundation of renowned research institutes, universities, and a number of successful cell therapy companies who have paved the way forward in this field.
Another local life sciences company is looking to go public.
Context Therapeutics, a Philadelphia biopharmaceutical company focused on women’s cancers, is seeking to raise about $20 million through its IPO.
In documents filed Monday with the Securities and Exchange Commission, Context states it intends to sell 1.5 shares million of its common stock to the public at $12 to $14 per share.
The company is poised to become the fifth Philadelphia-area life sciences to complete an IPO this year. That distinction, however, could go to Castle Creek Biosciences, a cell and gene therapy company based in Exton that filed plans to go public through a $100 million IPO in July. Neither company has set a specific date for their public offering.
Context plans to list its stock on Nasdaq under the symbol “CNTX.”
Pharmaceutical and biotech product development consultancy Boyds has opened its US office in the Philadelphia area and welcomed Katy Rudnick as vice president and head of US Regulatory Affairs to head up the newly established US company.
Data Center Firm DataBridge Sites Expands into Philadelphia, Maryland, and Chicago
Cloud, Colocation, and Interconnection offered in Key Data Center Markets
June 10, 2020 06:00 AM Eastern Daylight Time
SILVER SPRING, Md.–(BUSINESS WIRE)–Three proven multi-tenant data centers have been brought together as a single-service entity by DataBridge Sites, offering cloud, colocation, and interconnection services. The three data center campuses are located in Silver Spring, Maryland, convenient to both the Washington DC and Baltimore markets; King of Prussia, Pennsylvania, serving Philadelphia; and Aurora, Illinois, a proven data center destination near Chicago.
“Due to COVID-19, companies are transitioning even more aggressively to digital operations and the ability to always be available for their customers and employees is of even greater concern than ever before”
DataBridge Sites is a rebranding by 20-year old ESite Systems, which in 2019 purchased Maryland and Pennsylvania data centers that had been operated by former ownership under the Agile name. All three data centers have exceptional uptime records, well-established customer bases, and offer the range of services integral to true hybrid computing.
“Our portfolio of proven data centers offers colocation and cloud services as well as direct access to multiple public cloud providers and carrier hotels,”…
Forbes recently honored two Maryland biotech CEOs, naming them to the 50 Over 50 list of female visionaries. The local awardees are Helen Sabzevari of Precigen and Carol Nacy of Sequella. Sabzevari focuses on cancer treatment, and Nacy battles tuberculosis.
The Plymouth Group, which owns the property, has partnered with Centerbridge Partners, L.P. to turn the former Budd Plant in Philadelphia into a facility that will support biomanufacturing efforts of companies across Cellicon Valley. The new site will position Philadelphia as a key lynchpin in biomanufacturing and continue the city’s growth as one of the top biopharma hubs in the United States.
The Curtis, located in the heart of Center City Philadelphia, once housed Curtis Publishing, owner of beloved publications such as the Saturday Evening Post and Ladies Home Journal.
INOVIO Doses First Participant in Phase 2 Trial for its DNA Vaccine Against Middle East Respiratory Syndrome (MERS), a Coronavirus Disease
INOVIO (NASDAQ: INO), a biotechnology company bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that the company has dosed the first Phase 2 trial subject in its quest to develop the first vaccine against the Middle East Respiratory Syndrome (MERS). INOVIO’s Phase 2 trial is designed to evaluate INO-4700, its DNA vaccine candidate for the prevention of MERS, a disease in the coronavirus family for which there are no approved vaccines.